HOLX Hologic Inc

BEDFORD, Mass., June 11, 2014 /PRNewswire/ -- Hologic, Inc. (NASDAQ: HOLX) announced today that two products from its 3D mammography platform will be showcased at the Premier, Inc. 2014 Breakthroughs Conference and Exhibition in San Antonio, TX. Hologic's C-View software option (low-dose 3D mammography) and Affirm 3D-guided breast biopsy are two of only 16 medical innovations featured at the conference's sixth annual Innovation Celebration, an event that recognizes advances in healthcare while highlighting industry suppliers committed to innovation and improving patient outcomes. Selection criteria included the uniqueness of the product, the ability to have an impact on an unmet medical need, and the potential to improve patient care.

"We are honored to have our low-dose 3D mammography and 3D-guided breast biopsy products recognized at Premier's Innovation Celebration event," said Peter J. Valenti III, Division President, Breast Health. "In today's challenging environment, Hologic is committed to introducing innovative technologies that help detect disease earlier when the likelihood of successful treatment is at its greatest, improve patient outcomes, and lower costs to our healthcare partners. These two products are examples of this commitment and they are further evidence of our plans to make 3D mammography the gold standard in breast cancer screening and diagnosis."

"Those who attend and participate in the Innovation Celebration share Premier's commitment to providing valuable products to our members that are safe, high-quality and cost-effective," said Durral R. Gilbert, President of Supply Chain Services, Premier. "We believe these innovations can benefit providers as they work to transform healthcare."

Introduced in the U.S. in 2013, Hologic's C-View software is designed to generate 2D images from 3D mammography image slices, eliminating the need for a separate 2D exposure during a Hologic 3D mammography exam. This technology is designed to offer radiologists and patients a number of benefits including a reduction in x-ray exposures leading to shorter exam times (less than 4 second scan per view), and increased patient comfort from the shorter compression time. Published studies have shown that the use of Hologic's low-dose 3D mammography results in a clinically superior exam at virtually the same low radiation dose as a conventional 2D screening exam.[i]

Hologic's Affirm 3D-guided breast biopsy product  is a first-of-its-kind technology designed for the localization and accurate targeting of regions of interest and is especially important for targeting lesions not detected in 2D imaging or when using other modalities. Launched in 2013, this new biopsy technique is designed to provide numerous advantages over traditional stereotactic biopsy procedures, including faster lesion targeting and reduced patient procedure time.

About Hologic, Inc.:

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products. The Company operates four core business units focused on breast health, diagnostics, GYN surgical, and skeletal health. With a comprehensive suite of technologies and a robust research and development program, Hologic is committed to improving lives. The Company is headquartered in Massachusetts. For more information, visit www.hologic.com.

About Premier, Inc.:

Premier, Inc. is a leading healthcare improvement company, uniting an alliance of approximately 3,000 U.S. hospitals and 110,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost. Premier, a Malcolm Baldrige National Quality Award recipient, plays a critical role in the rapidly evolving healthcare industry, collaborating with members to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide. Headquartered in Charlotte, N.C., Premier is passionate about transforming American healthcare. Please visit www.premierinc.com for more information about the company.

Hologic, Affirm and C-View are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

Forward-looking Statement Disclaimer:

This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic C-View software and Affirm 3D-guided breast biopsy products. There can be no assurance these products will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the products can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.

[i] http://investors.hologic.com/2014-02-10-Three-New-Peer-reviewed-Publications-Further-Validate-the-Benefits-of-Hologic-3D-Mammography-Tomosynthesis-in-Breast-Cancer-Screening

SOURCE Hologic, Inc.